Phacilitate Leaders World

Speakers

Loading
Brad Smith

Brad Smith

VP, Advisory Services, Planning & Design Operations, IQVIA

As the Vice President of Translational Medicine, Brad leads biomarker and diagnostic strategy and planning interactions throughout the  IQVIA organization including clinical, laboratory, consulting and commercial projects.  He brings more than 20 years of experience in research in academia, biotechnology and clinical research including 8 years of experience in planning and design of clinical development plans and protocols for drug development.  Prior to Quintiles, Brad spent 10 years at Cell Signaling Technology responsible for technical, laboratory and corporate development of biomarker and diagnostic businesses.  He is the author of multiple basic research, translational medicine and clinical publications and patents, has Ph.D. from Stanford University and held post-doctoral positions at Stanford University and UCSF.

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK